DEFA14A: Entrada Therapeutics Bolsters Board with Appointment of Biopharma Veteran Dr. Maha Radhakrishnan

Entrada Therapeutics, Inc. announced the expansion of its Board of Directors and the appointment of Dr. Maha Radhakrishnan, a seasoned biopharmaceutical executive, effective June 1, 2025.

Summary

• Entrada Therapeutics, Inc. expanded its Board of Directors from six to seven members.
• Maha Radhakrishnan, M.D. was appointed as a Class III director, effective June 1, 2025, to serve until the company's annual meeting in 2027.
• Dr. Radhakrishnan was also appointed to the Audit Committee, replacing Kush Parmar, M.D., Ph.D., who will continue to serve as a member and Chairman of the Board.
• As compensation, Dr. Radhakrishnan will receive an initial stock option to purchase the lesser of a $500,000 value or 38,000 shares, vesting monthly over three years.
• She will receive an annual director fee of $40,000 and an annual Audit Committee fee of $9,000.
• Beginning in 2026, Dr. Radhakrishnan will also receive an annual stock option grant equal to the lesser of a $250,000 value or 19,000 shares, vesting upon the earlier of the first anniversary of the grant or the next Annual Meeting.
• The Board determined Dr. Radhakrishnan is independent under Nasdaq listing standards.
• Dr. Radhakrishnan brings extensive experience from roles at Sofinnova Investments, Biogen, Inc., Sanofi S.A., Bioverativ Inc., Bristol Myers Squibb, UnitedHealth Group, and Cephalon, Inc., as well as board service at Minovia Therapeutics and Alto Neuroscience, Inc.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced and independent director with a strong background in biopharmaceutical development and commercialization is a significant positive for corporate governance and strategic direction, indicating a strengthening of the company's leadership.

Positives

• The appointment of Dr. Maha Radhakrishnan, a highly experienced biopharmaceutical executive, significantly strengthens the Board's expertise in product development, commercialization, and medical functions.
• Her background at major companies like Biogen and Sanofi provides valuable strategic insights for Entrada Therapeutics.
• Dr. Radhakrishnan's determination as an independent director enhances corporate governance and oversight.
• The expansion of the board allows for the addition of new, relevant expertise without displacing existing valuable members.

Future Outlook

Dr. Radhakrishnan's appointment as a Class III director until the 2027 annual meeting, coupled with her eligibility for annual stock option grants starting in 2026, indicates a long-term commitment to leveraging her expertise in product development and commercialization for the company's strategic growth.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therapeutics, Inc. Date: June 3, 2025 /s/ Dipal Doshi Dipal Doshi Chief Executive Officer"

Industry Context

The appointment of a highly experienced executive like Dr. Radhakrishnan, with a background spanning major pharmaceutical companies (Biogen, Sanofi) and venture capital (Sofinnova), is a strategic move common in the life sciences industry. It reflects a company's commitment to strengthening its corporate governance, clinical development, and commercialization capabilities, which are critical for success in a competitive and innovation-driven sector.

Comparison to Industry Standards

• Expanding the board to include a highly qualified independent director is a common practice among growing biotechnology companies seeking to enhance strategic oversight and expertise.
• Dr. Radhakrishnan's extensive experience in medical affairs, product development, and commercialization at large biopharmaceutical companies like Biogen and Sanofi aligns with the industry's best practices for board composition, particularly for companies with a developing pipeline.
• The compensation structure, combining cash fees with performance-aligned stock options, is standard for non-employee directors in the biotechnology sector, designed to align their interests with long-term shareholder value.
• The explicit determination of Dr. Radhakrishnan's independence under Nasdaq listing standards demonstrates adherence to key corporate governance benchmarks, ensuring objective decision-making.

Management Changes

Corporate Governance

Related Party Transactions

• No arrangements or understandings between Dr. Radhakrishnan and any other person regarding her appointment were disclosed.
• No family relationships between Dr. Radhakrishnan and any director or executive officer were disclosed.
• No related person transactions (within the meaning of Item 404(a) of Regulation S-K) between Dr. Radhakrishnan and the Company were disclosed.

Stakeholder Impact

• Shareholders: Benefit from enhanced corporate governance and strategic oversight due to the addition of an experienced and independent director, potentially leading to better long-term decision-making and value creation.
• Management: Gains additional strategic guidance and expertise from a seasoned industry veteran, particularly in clinical development and commercialization.
• Employees: May benefit from stronger leadership and strategic direction, potentially contributing to more stable and growth-oriented company operations.

Next Steps

• Dr. Radhakrishnan will serve as a Class III director until the company's annual meeting of stockholders in 2027.
• Dr. Radhakrishnan will begin receiving annual stock option grants starting with the Annual Meeting to be held in 2026.

Key Dates

Recommendation

Keywords

Entrada Therapeutics, Board of Directors, Maha Radhakrishnan, Biotechnology, Pharmaceuticals, Corporate Governance, Audit Committee, SEC Filing, TRDA, Biogen, Sanofi, Sofinnova Investments